Program
SH006
A development code.
Its studies are mostly in Carcinoma, Hepatocellular · Liver Neoplasms, led by Nanjing Sanhome Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Sanhome Pharmaceutical | 22 open or running | phase 3since Jan 31, 2026 | Jan 7, 2026 | Dec 30, 2026phase 1 · NCT07362264 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2026First study: phase 1 study in Liver NeoplasmsFirst studyNCT07362264 · 50 enrolled · China
- Jan 31, 2026Phase 3 study in Carcinoma, HepatocellularPhase 3 reachedNCT07392866 · 120 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 1 study in Liver NeoplasmsNCT07362264
- Mar 1, 2030Primary completion: phase 3 study in Carcinoma, HepatocellularNCT07392866
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07392866Carcinoma, Hepatocellular · China | 3 | Not yet recruiting | Mar 1, 2030 | 120 |
| NCT07362264Liver Neoplasms · China | 1 | Active, not recruiting | Dec 30, 2026 | 50 |
How it is read
Names in the registry
- “SH006”, 2 entries
Codes read as this program: SH006.
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
- Liver Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.